QL1706 for advanced liver cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called QL1706 for people with advanced liver cancer that has worsened after a previous immunotherapy treatment. The goal is to see if it can help slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver function score (Child-Pugh) is 7 or less.
- You are able to go about daily activities on your own (ECOG score 0 or 1).
- Advanced liver cancer that has been confirmed by MRI and a biopsy.
- Your cancer got worse after at least one treatment that included an anti-PD-1 drug (like immunotherapy).
- You have not had treatment with an anti-CTLA-4 drug (like Yervoy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a special type of radiation (SBRT) and an immunotherapy drug (QL1706) as a second option for people with advanced liver cancer that hasn't been controlled by initial treatment.
This trial tests whether a combination of two drugs, QL1706 (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks blood supply to tumors), given before surgery can help shrink liver cancer and lower the chance of it coming back. It may be an option for people with certain types of liver cancer that are considered high-risk for recurrence.
This study tests QL1706 together with bevacizumab and/or chemotherapy as an initial (first) treatment for advanced liver cancer. It may help shrink tumors or control the disease when surgery or local treatments aren’t suitable.
This trial tests a new drug called QL1706 combined with standard chemotherapy and radiation to shrink liver tumors in patients with colon cancer that has spread to the liver. The goal is to make these tumors small enough to remove surgically.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.